AstraZeneca PLC AZNCF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AZNCF is a good fit for your portfolio.
News
-
AstraZeneca's Advanced Breast Cancer Drug Fails to Meet Primary Goals
-
AstraZeneca's Imfinzi Immunotherapy Gets U.S. FDA Approval for Endometrial Cancer
-
AstraZeneca's Farxiga Approved For Treating Pediatric Type-2 Diabetes in U.S.
-
AstraZeneca started at buy at Goldman, which rates GSK a neutral
-
AstraZeneca kicks off 'new era of growth' with aim to hit $80 billion of sales by 2030
-
AstraZeneca Targets $80 Billion Revenue by 2030 Through Pipeline Expansion
-
AstraZeneca Plans $1.5 Billion Manufacturing Facility in Singapore
-
France Secures $16 Billion From Microsoft, Amazon and Others at Foreign Investment Summit — Update
Trading Information
- Previous Close Price
- $160.45
- Day Range
- $153.00–160.42
- 52-Week Range
- $118.16–162.00
- Bid/Ask
- $151.98 / $164.28
- Market Cap
- $248.69 Bil
- Volume/Avg
- 2,577 / 3,216
Key Statistics
- Price/Earnings (Normalized)
- 21.71
- Price/Sales
- 5.26
- Dividend Yield (Trailing)
- 1.78%
- Dividend Yield (Forward)
- 1.78%
- Total Yield
- 1.78%
Company Profile
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Growth
- Total Number of Employees
- 89,900
- Website
- https://www.astrazeneca.com
Competitors
Valuation
|
Metric
|
AZNCF
|
LLY
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 21.71 | 94.64 | 58.75 |
Price/Book Value | 6.64 | 65.65 | 8.00 |
Price/Sales | 5.26 | 22.25 | 5.29 |
Price/Cash Flow | 24.82 | 92.48 | 18.59 |
Price/Earnings
AZNCF
LLY
MRK
Financial Strength
|
Metric
|
AZNCF
|
LLY
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.70 | 0.68 | 0.68 |
Current Ratio | 0.89 | 1.35 | 1.25 |
Interest Coverage | 5.32 | 14.11 | 3.97 |
Quick Ratio
AZNCF
LLY
MRK
Profitability
|
Metric
|
AZNCF
|
LLY
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 59.78% | 11.20% | 5.22% |
Return on Equity (Normalized) | 157.53% | 57.69% | 13.56% |
Return on Invested Capital (Normalized) | 88.21% | 20.65% | 8.29% |
Return on Assets
AZNCF
LLY
MRK
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Lgszwjsbh | Zwm | $841.1 Bil | |||
| Johnson & Johnson
JNJ
| Ssklwqng | Kktm | $351.3 Bil | |||
| Merck & Co Inc
MRK
| Nmqvdlnj | Hhl | $322.9 Bil | |||
| AbbVie Inc
ABBV
| Wbxtmpyz | Zslv | $299.6 Bil | |||
| AstraZeneca PLC ADR
AZN
| Tmwjmpmbtz | Snp | $244.3 Bil | |||
| Roche Holding AG ADR
RHHBY
| Blnwnrlqv | Zwrd | $222.8 Bil | |||
| Novartis AG ADR
NVS
| Fbcyfdqc | Dpd | $214.2 Bil | |||
| Amgen Inc
AMGN
| Ldkmcwnlt | Rdz | $162.7 Bil | |||
| Pfizer Inc
PFE
| Hqllsrgr | Zzgt | $152.9 Bil | |||
| Sanofi SA ADR
SNY
| Vrrrvxdl | Wtm | $117.4 Bil |